Latest news with #DTG
The Star
10 hours ago
- Health
- The Star
Proper DRG roll out can take more than six months, says private hospitals association
KUALA LUMPUR: A proper rollout of the diagnosis-related group (DRG) payment model could take more than six months given the complexities in data gathering and analysis, says the Association of Private Hospitals Malaysia (APHM), adding that it is ready to provide any help. Its president Datuk Dr Kuljit Singh said accurate clinical data and a national electronic health record system is needed for any DRG-type mechanism to work He said this foundational data is not available yet. "As the process of gathering and analysing such data is complex and time-consuming, APHM anticipates that a proper rollout will require considerably more than six months," he said. Dr Kuljit also said the APHM welcomed Health Minister Datuk Seri Dr Dzulkefly Ahmad's announcement that a basic medical and health insurance/takaful product would be introduced later this year and the DRG rolled out in phases. To support this national initiative, Dr Kuljit said APHM member hospitals have offered to share relevant clinical data with the Health Ministry and the Finance Ministry. "APHM strongly advocates that adequate time and resources are allocated to ensure that the DRG initiative is thoroughly conceptualised, piloted and implemented, to ultimately deliver sustainable improvements for all Malaysians," he said. The DRG payment system involves paying a fixed sum based on the diagnosis and treatment provided, rather than itemising each charge. It is said the DTG model can help regulate medical costs by limiting excessive charges. Examples of countries that have implemented this are Sweden, Canada and Australia. Earlier, in his opening speech, Dr Dzulkefly said introducing DRG in phases to pay for healthcare services, beginning with the base medical and health insurance/takaful products, would be a key driver for value-based healthcare. He also said the Health Ministry is hoping to introduce the DRG payment model by the end of 2025.
Business Insider
17-05-2025
- Business
- Business Insider
Daimler Truck Holding AG (DTG) Receives a Hold from UBS
UBS analyst Hemal Bhundia maintained a Hold rating on Daimler Truck Holding AG (DTG – Research Report) on May 15 and set a price target of €40.00. The company's shares closed yesterday at €39.67. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter In addition to UBS, Daimler Truck Holding AG also received a Hold from DZ BANK AG's Holger Schmidt in a report issued on May 14. However, yesterday, Citi maintained a Buy rating on Daimler Truck Holding AG (XETRA: DTG). The company has a one-year high of €45.33 and a one-year low of €29.61. Currently, Daimler Truck Holding AG has an average volume of 1.98M. Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of DTG in relation to earlier this year.
Al Bawaba
08-05-2025
- Business
- Al Bawaba
Epson unveils its first direct-to-film textile printer
Epson is proud to announce the release of its first Direct-to-Film (DTFilm) printer, the SC-G6000, the initial offering in a new line of Epson DTG and DTFilm printers. The new Epson 'G' series printer represents a significant advancement in textile printing technology, enabling users to create high-quality transfers across a wide array of fabric types. The SC-G6000 marks Epson's strategic entry into the expanding DTFilm market. The new roll-to-roll printer leverages Epson's dependable, versatile, and productive inkjet technology to provide a strong alternative in the marketplace. As a standalone device, the SC-G6000 is supported by dedicated reseller partners who offer essential accessories, including compatible powder shaker units, curing solutions, and other consumables. Unlike its competitors, the SC-G6000 eliminates the need for regular manual maintenance, thanks to its automated fabric wiping system. Traditional systems often rely on a rubber wiper that requires manual cleaning however the SC-G6000 sets itself apart by requiring minimal maintenance, with the white ink circulation system ensuring continuous production by preventing clogging and sedimentation. Epson's development of the SC-G6000 is in direct response to market demand, as garment printing gains prominence over conventional techniques like DTG, Heat Transfers and screen printing. The new printer complements Epson's current DTG and DTFilm hybrid solutions that are available with the SC-F1000, SC-F2200 and SC-F3000. The printer mechanics, PrecisionCore printhead, ink system and image processor are all based on the latest existing and proven Epson technologies, and the printer is fully integrated with Epson's user-friendly Edge Print Pro software. Advantages of the SC-G6000 include: Vivid and precise prints capable of producing striking, detailed as it is suitable for application on a variety of fabrics, not just labour with cleaning processes that reduce need for manual intervention. Specifications and key features include: Printhead: PrecisionCore MicroTFPPrint Width: 900mmInk Technology: UltraChrome DF, available in five colours (CMYK W), with a capacity of 1.6L per support with Epson EdgePrint Pro for optimised printing design with an intuitive touchscreen offering convenience, particularly for those new to DTFilm printing. Grant Cooke from Epson Europe's Commercial & Industrial printer division, comments: "As the first in Epson's direct-to-film range of 'G' series printers, the SC-G6000 demonstrates our enduring commitment to reliability, usability, and productivity. It combines proven technology with accessible features to deliver outstanding results, simplifying operational processes. This printer is an ideal solution for businesses looking to extend their textile printing capabilities with minimal complexity." The SC-G6000 conforms to all international standards, holding certifications such as GOTS and Eco Passport, ensuring environmental compliance and user safety. © 2000 - 2025 Al Bawaba (
Yahoo
03-05-2025
- Business
- Yahoo
At €35.59, Is Daimler Truck Holding AG (ETR:DTG) Worth Looking At Closely?
Daimler Truck Holding AG (ETR:DTG) saw a decent share price growth of 12% on the XTRA over the last few months. The recent rally in share prices has nudged the company in the right direction, though it still falls short of its yearly peak. With many analysts covering the large-cap stock, we may expect any price-sensitive announcements have already been factored into the stock's share price. But what if there is still an opportunity to buy? Today we will analyse the most recent data on Daimler Truck Holding's outlook and valuation to see if the opportunity still exists. Our free stock report includes 2 warning signs investors should be aware of before investing in Daimler Truck Holding. Read for free now. Good news, investors! Daimler Truck Holding is still a bargain right now according to our price multiple model, which compares the company's price-to-earnings ratio to the industry average. We've used the price-to-earnings ratio in this instance because there's not enough visibility to forecast its cash flows. The stock's ratio of 9.45x is currently well-below the industry average of 19.69x, meaning that it is trading at a cheaper price relative to its peers. Although, there may be another chance to buy again in the future. This is because Daimler Truck Holding's beta (a measure of share price volatility) is high, meaning its price movements will be exaggerated relative to the rest of the market. If the market is bearish, the company's shares will likely fall by more than the rest of the market, providing a prime buying opportunity. Check out our latest analysis for Daimler Truck Holding Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it's the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. Daimler Truck Holding's earnings over the next few years are expected to increase by 43%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value. Are you a shareholder? Since DTG is currently below the industry PE ratio, it may be a great time to increase your holdings in the stock. With a positive outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as capital structure to consider, which could explain the current price multiple. Are you a potential investor? If you've been keeping an eye on DTG for a while, now might be the time to make a leap. Its buoyant future profit outlook isn't fully reflected in the current share price yet, which means it's not too late to buy DTG. But before you make any investment decisions, consider other factors such as the track record of its management team, in order to make a well-informed investment decision. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. To that end, you should learn about the 2 warning signs we've spotted with Daimler Truck Holding (including 1 which is concerning). If you are no longer interested in Daimler Truck Holding, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
01-05-2025
- Health
- Yahoo
WHO warns Trump cuts put millions of HIV patients at risk
The World Health Organisation (WHO) has raised serious concerns that HIV medication shortages sparked by cuts to USAID will increase resistance to crucial treatment, The Independent can reveal. Leading epidemiologists have raised fears that shortages could reduce the effectiveness of the most commonly used HIV drug, dolutegravir (DTG), which is used by around 27 million people. This could leave patients without an alternative treatment. Professor Andrew Phillips, at University College London, has created a model predicting resistance in HIV patients to DTG. He warns the number of people currently resistant to the drug could 'easily at least double in six months' if people take less than one pill per day due to supply fears. 'If resistance starts to grow, this is a substantial problem for long-term HIV control in lower- and middle-income countries,' Prof Phillips said. 'If there is a new reality for another year that people are taking less than 70 per cent of their doses, then it would start to feel like a real concern for building up resistance.' A WHO spokesperson told this publication it 'remains very concerned that we will not have a suitable replacement option for dolutegravir that is as easy to take, with low side effects, delivered at low cost, and safe for all, including children and pregnant women'. 'We should be doing all that we can to protect this first-line treatment and to ensure that the worst-case scenario of increased drug resistance projected by this UCL modelling exercise does not occur,' they added. Because DTG-based treatment is intended to be taken daily, 'intermittent use of DTG-based anti-retroviral treatment due to drug shortages is likely to lead to increased drug resistance, and we worry about this scenario'. The warning comes after The Independent revealed the impact that sudden pauses by the Trump administration on the US President's Emergency Plan for Aids Relief (PEPFAR) are having on the ground, with patients in countries across sub-Saharan Africa running out of medication. On Mr Trump's first day in office, he froze almost all US foreign assistance funds for 90 days, while projects were reviewed to make sure they were aligned with 'American interests'. Aids-related deaths could jump by four million to 10 million by 2030 unless US foreign aid money is reinstated, according to forecasts from the UN Aids agency (UNAIDS). The Independent recently travelled to Uganda and Zimbabwe to see the impact of severing aid to those suffering from HIV. Among them was Hadja, who was pregnant and terrified that she would not be able to protect her unborn child. She described visiting hospitals where neither doctors nor drugs were available. James, a 50-year-old father of four, is also HIV positive and has not had access to HIV medication for over a month and a half. Without antiretroviral drugs, James's emaciated body is shutting down. The US government is expected to review its decision to stop PEPFAR, but there has been no indication that funding will resume. UNAIDS deputy executive director Angeli Achrekar told The Independent that drug shortages on the ground are 'a recipe for disaster' in terms of increased drug resistance. She said: 'When we have drug resistance to the medication that people are on, they have to be put on second- or third-line therapy, which is much more expensive and much more difficult to access. Coupled with all these new infections, that is a recipe for disaster.' Dolutegravir (DTG) is currently the first- and second-line treatment for HIV, with 90 per cent of the 30 million people living with HIV on a treatment regimen that includes this drug. Currently, resistance to DTG is low, at around 4 per cent, but for groups of patients who have already become resistant to previous antiretroviral regimes, prevalence jumps to 19 per cent. 20 January: Donald Trump orders a freeze on all foreign aid with a 90-day review 24 January: A stop-work order is issued to US aid-funded programmes 1 February: Limited exceptions are granted for "urgent lifesaving HIV treatment', but a lack of clarity and loss of staff mean services are still disrupted February: Funding decisions are challenged in various courts; the Trump administration fights orders to pay aid partners. By 10 March: Most aid grants and contracts are cancelled worldwide 25 March: Authorisation for the world's largest HIV programme, funded by the US, expires By 28 March: US Agency for International Development (USAID) shutdown confirmed, nearly all staff sacked Professor Brooke Nichols, an infectious disease mathematical modeller and health economist, told The Independent: 'If you have tens of thousands of people thinking they need to ration and take treatment intermittently, and you don't keep the virus fully suppressed, then when the virus rebounds, it could mutate and develop resistance to whatever drug is circulating. 'That is the really scary tipping point for resistance.' Anyone who develops multi-drug-resistant strains of HIV may need second- or third-line treatment, which costs at least $405 (£305) in lower-income countries: a sixfold increase on the cost of first-line antiretrovirals. Jeffrey Eaton, senior research fellow in HIV epidemiology at Imperial College London, also warned that if people become resistant to a HIV medication, 'they could transmit that resistance and then newly infected people might not be able to use dolutegravir'. Clinicians in the worst-hit areas have also told The Independent they're seeing worrying interruptions in HIV antiretroviral drug supplies. One clinic, the Family Hope Centre in southern Uganda – a country where 70 per cent of the HIV/Aids response was funded by PEPFAR – had to close for a month recently because, without foreign aid, it was unable to afford the rent, water and electricity bills. Irene Anamu, the Family Hope Centre's administrative director, told The Independent the centre has already seen a rise in clients contracting infections, including tuberculosis. She is now worried that the gaps in treatment will allow the virus in patients' bodies to replicate, 'meaning more drug-resistant clients', and strains which could spread past Uganda's borders. A US State Department spokesperson said: 'As directed by the secretary of state, urgent life-saving HIV care and treatment and prevention of mother-to-child transmission services are ongoing. As part of the overall foreign assistance review, all PEPFAR-funded services are currently being reviewed for assessment of programmatic efficiencies and consistency with United States foreign policy.' This article is part of The Independent's Rethinking Global Aid project
